FindTrial
Sign In

Prevention of Corticosteroid-induced Glucose Intolerance

Treatment With Rosiglitazone for the Prevention of Glucose Intolerance in Patients Treated With Corticosteroids

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00240604
Enrollment
100
Registered
2005-10-18
Start date
2005-04-30
Completion date
2015-10-31
Last updated
2011-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glucose Intolerance

Keywords

corticosteroid treatment, inflammatory diseases

Brief summary

Glucose intolerance is frequent and serious complication of corticosteroid therapy. the aim of the study is to examine the hypothesis that co treatment with rosiglitazone can prevent glucose intolerance in patients treated with corticosteroids.

Detailed description

Glucose intolerance is frequent and serious complication of corticosteroid therapy. the aim of the study is to examine the hypothesis that co treatment with rosiglitazone can prevent glucose intolerance in patients treated with corticosteroids.

Interventions

DRUGRosiglitazone

4 mg rosiglitazone per day

Sponsors

Hadassah Medical Organization
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* corticosteroid treatment

Exclusion criteria

* congestive heart failure pedal edema

Design outcomes

Primary

MeasureTime frame
plasma glucose concentration6 months

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026